Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.

BMC Cancer · 2015 · PMC4378224 · PMID 25884806

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the subgroup analyses, CHEK2 H371Y mutation carriers had a higher pCR rate than did non-carriers in both neoadjuvant anthracycline-based regimens and taxane-based regimens, although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.